Ceftolozane-tazobactam for the Treatment of Respiratory Infections Due to

Status Active, not recruiting

Clinical Trial Summary

The aim of this study is to report our experience with ceftolozane-tazobactam and to evaluate its safety and efficacy in the treatment of ICU dependent nosocomial respiratory tract infections due to extensively drug resistant Pseudomonas aeruginosa. Different dosing regimes of ceftalozane-tazobactam is evaluated and compared to the standard therapy of Colomycin.

Clinical Trial Description

Ceftolozane-tazobactam (C/T) is a novel type of beta-lactam/beta-lactamase inhibitor antibiotics targeting nosocomial infections caused by Gram-negative bacteria. In recent years, ceftolozane-tazobactam was prescribed for treating complicated urinary tract infections (cUTI) and complicated intraabdominal infections (cIAI). Following the results of ASPECT-NP trial in 2019, it was approved as a therapeutic option in nosocomial pneumonia including hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP).

The drug shows an excellent activity against ESBL-producing Enterobacterales and multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Pseudomonas aeruginosa. The latter is widely recognized as a common pathogen of nosocomial respiratory tract infections.

There is still a need for observations of clinical experiences to better define the risk-benefit profile of ceftolozane-tazobactam. The aim of this study is to report our experience with ceftolozane-tazobactam and to evaluate its safety and efficacy in the treatment of ICU dependent nosocomial respiratory tract infections due to extensively drug resistant Pseudomonas aeruginosa. Different dosing regimes of ceftalozane-tazobactam is evaluated and compared to the standard therapy of Colomycin. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04352855
Study type	Observational
Source	Semmelweis University
Contact
Status	Active, not recruiting
Phase
Start date	January 18, 2018
Completion date	May 19, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03937947` - Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
Not yet recruiting	`NCT04057625` - Transthoracic Ultrasound in the Diagnosis and Follow-up of Ventilator Associated Pneumonia	N/A
Not yet recruiting	`NCT03267693` - Gastrointestinal Complications in Association With Oropharyngeal and Respiratory Infections in Mechanical Ventilation	N/A
Completed	`NCT00726167` - Serum Procalcitonin Study in the Management of Ventilated Patients	N/A
Completed	`NCT02078999` - Biomarkers in Patients Undergoing Mechanical Ventilation	N/A
Recruiting	`NCT05124977` - Antimicrobial Stewardship For Ventilator Associated Pneumonia in Intensive Care	N/A
Recruiting	`NCT05331885` - A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2	Phase 3
Completed	`NCT05517759` - Application of VAP Bundle Among ICU Nurses
Active, not recruiting	`NCT04488510` - Pathogens Involved in Secondary Infections During Severe Forms of Covid-19 Pneumonia:
Completed	`NCT03917888` - Clinical Impact of Lung Ultrasound Monitoring for Diagnosis of VAP	N/A
Not yet recruiting	`NCT06066489` - Effect of Educational Program About Preventive Care Bundle for Prevention of Ventilator Associated Pneumonia Among Newborns	N/A
Completed	`NCT02096328` - Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia	Phase 2
Terminated	`NCT00771719` - Open Label Pharmacokinetic in Adult Patients With Ventilator-Associated Pneumonia	Phase 1
Recruiting	`NCT05696093` - Efficacy of Cotrimoxazole as a De-escalation Treatment of Ventilator-Associated Pneumonia in Intensive Care Unit	Phase 3
Recruiting	`NCT05354778` - HYDROcortisone Versus Placebo for Severe HospItal-acquired Pneumonia in Intensive Care Patients: the HYDRO-SHIP Study	N/A
Not yet recruiting	`NCT06059040` - Effect of Eliminating Gastric Residual Volume Monitoring on Ventilator Associated Events	N/A
Completed	`NCT04563104` - Lung Ultrasound in Procalcitonin- Guided Antibiotic Discontinuation in Ventilator Associated Pneumonia
Terminated	`NCT01975350` - Efficacy Study of Colistimethate Sodium Inhalation in Patients With Ventilator-associated Pneumonia
Recruiting	`NCT06000761` - Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit	N/A
Not yet recruiting	`NCT03294837` - Treatment of Ventilator Associated Pneumonia in Pediatric Intensive Care Unit	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Ceftolozane-tazobactam for the Treatment of Respiratory Infections Due to Extensively Drug-resistant Pseudomonas Aeruginosa Among Critically Ill Patients: a Retrospective Study.

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms